Effects of fasudil combined with rosuvastatin in the treatment of vascular dementia on patients' cognitive function, C-reactive protein and oxidative stress

doi:10.12092/j.issn.1009-2501.2018.10.011

Abstract

Abstract:

AIM: To investigate the effects of fasudil combined with rosuvastatin in the treatment of vascular dementia (VD) on patients' cognitive function, C-reactive protein and oxidative stress. METHODS: One hundred and eighty-four VD patients were selected as study subjects. They were divided into the rosuvastatin group and the combined drug group (fasudil + rosuvastatin) according to the random number table method. Each group contains 92 cases. MMSE (Mini-Mental State Examination), MoCA (Montreal Cognitive Assessment) and ADL (Activities of Daily Living) scores, the level of CRP (C-reactive protein), MDA (malondialdehyde), Hcy (serum homocysteine) and SOD (superoxide dismutase), as well as blood lipid index (TC, TG, LDL-C, HDL-C) levels, clinical efficacy and incidence of adverse reaction were compared between the two groups before and after treatment. RESULTS:The total effective rate of the combined drug group (93.48%) was significantly higher than that of the rosuvastatin group (82.61%), and the difference was statistically significant (P<0.05). After treatment, the MMSE, MoCA and ADL scores of the combined drug group were significantly higher than that of the rosuvastatin group, while the level of CRP, MDA, Hcy, TC, TG and LDL-C was significantly lower than that of the rosuvastatin group, and the SOD level was significantly higher than that of the rosuvastatin group, which were of statistically significant difference (P<0.05). There was no significant difference in the incidence of adverse reaction (P>0.05). CONCLUSION: Fasudil combined with rosuvastatin in the treatment of VD can improve patients' cognitive function and daily living ability, reduce oxidative stress response and the level of C-reactive protein, and improve patients' blood lipid index. This method is of significant clinical efficacy and high safety.

Key words: vascular dementia, fasudil, rosuvastatin, cognitive function, C-reactive protein, oxidative stress

CLC Number:

R743

CHEN Juanyan, SONG Shuijiang, XU Dongjuan, XU Qiong, LI Hongfei. Effects of fasudil combined with rosuvastatin in the treatment of vascular dementia on patients' cognitive function, C-reactive protein and oxidative stress[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1153-1158.

References

［1］Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia［J］. Alzheimers Dementia, 2014, 10(3): 296-302.
［2］张潇,曾鼎华.普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察［J］.中国药房, 2017, 28(5): 649-652.
［3］Utkan T, Yazir Y, Karson A, et al. Etanercept improves cognitive performance and increases eNOS and BDNF expression during experimental vascular dementia in streptozotocin-induced diabetes［J］. Curr Neurovasc Res, 2015, 12(2): 135-146.
［4］岳蕴华,白旭东,张小宁,等.普罗布考联合阿托伐他汀对脑梗死患者血清hs-CRP、ox-LDL、MMP-9水平及颈动脉斑块的影响［J］.中国神经精神疾病杂志,2014,40(11):641-645.
［5］李晓凤,朱伟,王薇.盐酸法舒地尔治疗急性缺血性脑卒中的临床观察［J］.中华老年心脑血管病杂志,2009,11(8):628.
［6］李波,刘微微,沃金善.瑞舒伐他汀对代谢综合征患者血清血管生成素2和炎症因子水平的影响［J］.中国全科医学,2012,15(21):2402-2404.
［7］华先平,杨勇,娄国平,等.瑞舒伐他汀对颈动脉粥样硬化患者颈动脉内中膜厚度及血清炎症因子的影响［J］.中国循环杂志,2011,26(3):198-201.
［8］中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)［J］. 中华精神科杂志, 2001,34(3): 1006-7884.
［9］宋淑霞,孟宪玲.法舒地尔对老年急性缺血性脑卒中患者神经功能缺损和血液流变学的影响［J］.中国老年学杂志,2012,32(5):1043-1045.
［10］中华医学会神经病学分会. 血管性痴呆诊断标准草案［J］.中华神经科杂志, 2002, 35(4):246.
［11］Barker R, Ashby EL, Wellington D, et al. Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia［J］. Brain,2014,137(Pt 5):1524-1532.
［12］卢昌均,周哲屹,刘国成,等.血管性痴呆发病机制的研究进展［J/CD］. 中华脑科疾病与康复杂志: 电子版,2014,4(3):41-44.
［13］刘春丽,陈虹,姜勇,等.松果菊苷对血管性痴呆大鼠行为学、氧自由基以及胆碱能神经递质代谢速率的影响［J］.中国药理学通报,2013,29(7): 1035-1036.
［14］Gustaw RK, Kowalczuk K, Stryjecka ZM. Lipids' peroxidation markers in Alzheimer's disease and vascular dementia［J］. Geriatr Gerontol Int, 2010,10(2): 161-166.
［15］林正,余智,曾博,等.［Gly14］-Humanin减轻大鼠颅脑外伤后氧化应激及细胞凋亡［J］.中国神经精神疾病杂志,2016,42(3):180-183.
［16］Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy［J］. J Neurol Sci, 2004, 226 (1/2): 25-29.
［17］Gibson CL, Srivastava K, Sprigg N, et al. Inhibition of Rho-kinase protects cerebral barrier from ischemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions［J］. J Neurochem,2014, 129 (5): 816-826.
［18］顾燕红,付顺昆,乔青燕,等.法舒地尔对HK-2细胞氧化应激及内质网应激的影响［J］.临床和实验医学杂志,2018,17(6):586-589.
［19］Santos DB, Colle D, Moreira EL, et al. Probucol, a lipidlowering drug，prevents cognitive and biochemical changes in mice［J］. Neuroscience, 2015, 284(12): 590-600.
［20］Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)［J］. Am J Cardiol, 2003,92(2): 152-160.
［21］刘文铠,蔡志雄,周晓燕,等.盐酸法舒地尔联合低分子肝素对缺血性脑卒中患者APTT、PT、FIB及治疗效果的影响［J］.中国老年学杂志,2017,37(14):3463-3465.
［22］Fukuta T, Asai T, Sato A, et al. Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil［J］. Pharm, 2016,506 (1/2): 129-137.

[1]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[2]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[3]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[4]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[5]	ZHU Haobin, YUE Hongmei, WU Xingdong, LIU Miaomiao, LI Yating, XU Jinhui. Research progress on the role of the Nrf2 signaling pathway in the complications associated with obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1283-1291.
[6]	YANG Zhian, ZHAO Yan, HE Yao, LIU Weiying, YU Qin. Pyroptosis mediated renal injury caused by chronic intermittent hypoxia and the intervention effect of edaravone in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 10-18.
[7]	HUA Haiyan, YAN Jie, QIN Yufen. Experimental study of schisandrin B attenuates acute myocardial ischemia injury in rats by inhibiting cardiomyocyte apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 848-856.
[8]	WANG Jinhuo, GAO Xinyue, GUO Jianrong. Effect of COX-2 inhibitors on postoperative delirium in elderly patients undergoing orthopedic surgery and its possible mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 863-869.
[9]	LI Xueheng, LI Long. Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
[10]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[11]	REN Yixing, LENG Yufang, GUO Mingjun, ZHANG Jianmin, SHI Yajing, CHEN Feng, LIU Xin. Role and mechanism of SIRT3 in attenuation of intestinal ischemia-reperfusion injury by dexmedetomidine in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 253-259.
[12]	LI Yongliang, LIN Haiyan, ZHANG Lingling, DONG Yilong. Effects of preoperative dezocine patient-controlled analgesia pump on stress response and cognitive function in elderly patients with lower extremity fractures [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 302-306.
[13]	HE Liyang, WEI Wenjie, YIN Qin, LIU Lijing, ZHONG Boying, LIU Cungen, ZHOU Meiling, HE Jianbin. Preventive and therapeutic effects of the Kiwi fruit essence (unsaturated fatty acid of actinidia chinesis planch seed oil) on radiation-induced lung injury rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 154-162.
[14]	LIN Naping, WU Yutang, HUANG Defen, XU Chaoxiang. Effects of miR-195-5p on ox-LDL-induced vascular endothelial cell injury through regulating FBXW7 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 163-170.
[15]	LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei. Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.